Algorae Pharmaceuticals Ltd - Company Profile
Powered by 
All the sales intelligence you need on Algorae Pharmaceuticals Ltd in one solution.
- Save hours of research time with a comprehensive
Sales Intelligence Solution.
- Understand how Algorae Pharmaceuticals Ltd fits into your total
addressable market and Ideal Customer Profile.
- Gain competitive edge with triggers that tell you
when and how to engage with Algorae Pharmaceuticals Ltd.
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Business Description
Algorae Pharmaceuticals Ltd (Algorae Pharmaceuticals) is a biotechnology company that focus on discovery, development and commercialization of novel therapeutics for improving the wellbeing of people with debilitating conditions such as cardiovascular disease, Parkinson’s disease and dementia. The company operates through one reportable segment which includes the research and development into living cell technologies, predominantly in New Zealand. The company is also developing its technology platform AlgoraeOS.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
R&D Overview
Algorae Pharmaceuticals R&D focuses on AI-powered drug discovery through its platform, AlgoraeOS. This platform, developed in collaboration with the UNSW AI Institute and CSIRO Data61, aims to generate high-confidence novel drug-combination candidates for complex diseases. The platform's predictive capabilities are continuously enhanced through a closed-loop system that integrates data from various stages of drug discovery and pre-clinical development. AlgoraeOS has been independently validated by the Peter MacCallum Cancer Centre, demonstrating its ability to prioritize drug combinations for laboratory investigation. The R&D unit of Algorae Pharmaceuticals is primarily the UNSW AI Institute, which collaborates with the UNSW Data Science Hub (uDASH). This unit is responsible for developing computational models and advanced AI methods to diagnose and treat complex diseases, transforming complex biological data into actionable drug discovery insights. Algorae Pharmaceuticals has established major technology alliances with the UNSW AI Institute, CSIRO Data61, and the Peter MacCallum Cancer Centre. The company has filed patents for two priority licensing candidates, AI-116 and AI-168, and has a pipeline that includes these candidates along with the NTCELL program. In FY2026, the company spent AUD0.9 million on its R&D activities.
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer